Cargando…
Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057081/ https://www.ncbi.nlm.nih.gov/pubmed/36992428 http://dx.doi.org/10.3390/v15030719 |
_version_ | 1785016275688226816 |
---|---|
author | Laforêt, Fanny Antoine, Céline Lebrun, Sarah Gonza, Irma Goya-Jorge, Elizabeth Douny, Caroline Duprez, Jean-Noël Scippo, Marie-Louise Taminiau, Bernard Daube, Georges Fall, Abdoulaye Thiry, Damien Delcenserie, Véronique |
author_facet | Laforêt, Fanny Antoine, Céline Lebrun, Sarah Gonza, Irma Goya-Jorge, Elizabeth Douny, Caroline Duprez, Jean-Noël Scippo, Marie-Louise Taminiau, Bernard Daube, Georges Fall, Abdoulaye Thiry, Damien Delcenserie, Véronique |
author_sort | Laforêt, Fanny |
collection | PubMed |
description | New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed on intestinal microbiota, using an in vitro model: the SHIME(®) system (Simulator of the Human Intestinal Microbial Ecosystem). After stabilization of the system, the phage was inoculated for 7 days and its persistence in the different colons was studied until its disappearance from the system. The concentration of short chain fatty acids in the colons showed good colonization of the bioreactors by the microbiota and no significant effect related to the phage treatment. Diversity (α and β), the relative abundance of bacteria, and qPCR analysis targeting different genera of interest showed no significant variation following phage administration. Even if further in vitro studies are needed to assess the efficacy of this phage against its bacterial host within the human intestinal ecosystem, the phage ULIP33 exerted no significant change on the global colonic microbiota. |
format | Online Article Text |
id | pubmed-10057081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100570812023-03-30 Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model Laforêt, Fanny Antoine, Céline Lebrun, Sarah Gonza, Irma Goya-Jorge, Elizabeth Douny, Caroline Duprez, Jean-Noël Scippo, Marie-Louise Taminiau, Bernard Daube, Georges Fall, Abdoulaye Thiry, Damien Delcenserie, Véronique Viruses Article New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed on intestinal microbiota, using an in vitro model: the SHIME(®) system (Simulator of the Human Intestinal Microbial Ecosystem). After stabilization of the system, the phage was inoculated for 7 days and its persistence in the different colons was studied until its disappearance from the system. The concentration of short chain fatty acids in the colons showed good colonization of the bioreactors by the microbiota and no significant effect related to the phage treatment. Diversity (α and β), the relative abundance of bacteria, and qPCR analysis targeting different genera of interest showed no significant variation following phage administration. Even if further in vitro studies are needed to assess the efficacy of this phage against its bacterial host within the human intestinal ecosystem, the phage ULIP33 exerted no significant change on the global colonic microbiota. MDPI 2023-03-10 /pmc/articles/PMC10057081/ /pubmed/36992428 http://dx.doi.org/10.3390/v15030719 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Laforêt, Fanny Antoine, Céline Lebrun, Sarah Gonza, Irma Goya-Jorge, Elizabeth Douny, Caroline Duprez, Jean-Noël Scippo, Marie-Louise Taminiau, Bernard Daube, Georges Fall, Abdoulaye Thiry, Damien Delcenserie, Véronique Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title | Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title_full | Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title_fullStr | Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title_full_unstemmed | Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title_short | Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model |
title_sort | impact assessment of vb_kpnp_k1-ulip33 bacteriophage on the human gut microbiota using a dynamic in vitro model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057081/ https://www.ncbi.nlm.nih.gov/pubmed/36992428 http://dx.doi.org/10.3390/v15030719 |
work_keys_str_mv | AT laforetfanny impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT antoineceline impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT lebrunsarah impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT gonzairma impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT goyajorgeelizabeth impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT dounycaroline impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT duprezjeannoel impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT scippomarielouise impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT taminiaubernard impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT daubegeorges impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT fallabdoulaye impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT thirydamien impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel AT delcenserieveronique impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel |